Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2 -agonist, vilanterol (VI) combination in reducing COPD exacerbations Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Inhaled vilanterol trifenatate/fluticasone furoate (VFF) improves respiratory muscle function and walking performance in severe COPD without change in pulmonary function Source: International Congress 2017 – Management of COPD Year: 2017
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessment Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Fluticasone furoate (FF): Prolonged duration of action compared with other ICS Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Mometasone furoate 400 μg once daily is more efficacious than budesonide 400 μg once daily in improving asthma symptoms in patients with moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Lung function and symptom improvements with fluticasone propionate/salmeterol 250/50 and ipratropium/albuterol in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Inhaled vilanterol trifenatate/fluticasone furoate increases maximum diaphragm contraction in severe COPD Source: International Congress 2014 – Clinical physiology and respiratory muscles Year: 2014
Health-related quality of life effects of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003
Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003